Chemomab Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2018
Selling, General & Admin	3.41	7.08	11.56	6.03	1.29	Upgrade
Research & Development	11.33	18.38	16.98	6.33	4.68	Upgrade
Operating Expenses	14.74	25.46	28.53	12.37	5.97	Upgrade
Operating Income	-14.74	-25.46	-28.53	-12.37	-5.97	Upgrade
Interest Expense	-	-	-	-0.11	-	Upgrade
Interest & Investment Income	0.79	1.25	0.96	-	0.04	Upgrade
Currency Exchange Gain (Loss)	-	-0.01	-0.61	-	-0.02	Upgrade
Pretax Income	-13.95	-24.22	-28.18	-12.48	-5.95	Upgrade
Income Tax Expense	-	-	-0.53	-	-	Upgrade
Net Income	-13.95	-24.22	-27.65	-12.48	-5.95	Upgrade
Net Income to Common	-13.95	-24.22	-27.65	-12.48	-5.95	Upgrade
Shares Outstanding (Basic)	16	12	11	10	7	Upgrade
Shares Outstanding (Diluted)	16	12	11	10	7	Upgrade
Shares Change (YoY)	38.15%	3.26%	9.70%	51.71%	-	Upgrade
EPS (Basic)	-0.86	-2.06	-2.43	-1.20	-0.87	Upgrade
EPS (Diluted)	-0.86	-2.06	-2.43	-1.20	-0.87	Upgrade
Free Cash Flow	-	-23.61	-20.44	-12.61	-5.28	Upgrade
Free Cash Flow Per Share	-	-2.01	-1.80	-1.22	-0.77	Upgrade
EBITDA	-14.67	-25.39	-28.48	-12.33	-5.95	Upgrade
D&A For EBITDA	0.07	0.07	0.06	0.03	0.02	Upgrade
EBIT	-14.74	-25.46	-28.53	-12.37	-5.97	Upgrade

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q